Clinical Study of Oncolytic Vaccinia VIrus Delivering Targeted CD19 in Vivo CAR-T/M Therapy for Refractory/Relapsed B-cell Lymphoma

Trial Details

NCT ID

NCT07398963

Phase

PHASE1

Sponsor

Second Affiliated Hospital, Zhejiang University, School of Medicine

Status

RECRUITING

Cancer Type

Lymphoma

Interventions

• CD19-CAR novel oncolytic vaccinia virus

Locations (sample)

• Hangzhou, Zhejiang, China|30.29365,120.16142

Key Eligibility Criteria

• Age≥ 18 years old, up to 75 years old, male or female;
• ECOG score 0-2;
• Histologically confirmed non-Hodgkin B-cell lymphoma (NHL) \[diagnostic criteria are WHO2008\], including diffuse large B-cell lymphoma (DLBCL) non…
• CD19 positive (immunohistochemistry or flow cytometry);

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.